Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia
Launched by PIERRE FABRE MEDICAMENT · Dec 20, 2012
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women 18-45 years old with iron deficiency anaemia
- • haemoglobin level between 85 g/L and 105 g/L
- • serum ferritin level \< 15 µg/L
- • D14 + 7 days of the menstruation cycle on the day of pharmacokinetic evaluation
- • Standard diet
- Exclusion Criteria:
- • - Anaemia related to other causes than iron deficiency and particularly inflammatory anaemia, anaemia due to marrow failure, haemopathy, haemoglobinopathies (sickle cell disease, thalassemia), haemolytic anaemia, anaemia due to acute haemorrhage, or anaemia related to chronic renal failure,
- • Haemochromatosis or iron overload of secondary origin (blood transfusion),
- • Long term treatment known to modify iron absorption,
- • Gastro duodenal ulcer,
- • Inflammatory bowel disease or any digestive disease which could modify iron absorption,
- • Fructose intolerance, syndrome of malabsorption of glucose, galactose, deficit of sucrase-isomaltase,
- • Serious or progressive disease (cardiac, pulmonary, hepatic, renal, haematological, malignancy, autoimmune disease, infectious disease or neuropsychiatric disorders),
- • Surgery undergone within 1 month prior to selection visit or a surgery planned during the study realization.
About Pierre Fabre Medicament
Pierre Fabre Medicament is a global pharmaceutical company dedicated to improving patient health through innovative therapies and high-quality healthcare solutions. With a strong emphasis on research and development, Pierre Fabre focuses on oncology, dermatology, and consumer health, striving to address unmet medical needs and enhance patient outcomes. The company is committed to ethical practices in clinical trial sponsorship, ensuring rigorous adherence to regulatory standards while fostering collaboration with healthcare professionals and stakeholders. Through its dedication to scientific excellence and patient-centric approaches, Pierre Fabre Medicament plays a vital role in advancing medical knowledge and therapeutic options worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iasi, , Romania
Timisoara, , Romania
Iasi, , Romania
Timisoara, , Romania
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials